glp-1 obesity drug news october 2025 Novo, Lilly weight-loss drugs should be first option treatments, European doctors say Eli Lilly to seek approval

Ahmed GU et al

doi: 10.1126/science.1092952

Rare reports of clotting events have occurred in some people taking GLP-1 drugs, but health experts havent confirmed that the medications themselves caused the clots

GLP-1 medicines induce substantial metabolic improvements in the liver, with reduction in liver weight and lipid accumulation largely attributed to weight loss

Obesity GLP-1 Market Analysis - Size, Share, and Forecast Outlook 2025 to 2035 Industry Size (2025): USD 8,169 Mn Forecast (2035): USD 65,364 Mn CAGR (2025 to 2035): 23.1% Obesity GLP-1 Market Forecast and Outlook 2025 to 2035 The obesity GLP-1 market is projected to grow from USD 8169 million in 2025 to approximately USD 65,364 million by 2035, recording an absolute increase of USD 57,195 million over the forecast period

Reactivating dormant follicles Pelage Pharmaceuticals is pursuing a metabolic approach rooted in emerging insights into hair follicle stem cell (HFSC) biology